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Abstract
Overcoming dendritic cell (DC) dysfunction is a prerequisite for
successful active immunotherapy against breast cancer. CD40
ligand (CD40L), a key molecule in the interface between T-lympho-
cytes and DCs, seems to be instrumental in achieving that goal.
Commenting on our data that CD40L protects circulating DCs
from apoptosis induced by breast tumor products, Lenahan and
Avigan highlighted the potential of CD40L for immunotherapy. We
expand on that argument by pointing to additional findings that
CD40L not only rescues genuine DCs but also functionally
improves populations of immature antigen-presenting cells that fill
the DC compartment in patients with breast cancer.
Crucial to the role of dendritic cells (DCs) as immune
sentinels is their capacity to interact with lymphocytes [1].
This interaction mediates bi-directional signaling; DCs
activate T lymphocytes (both CD4 and CD8) in an antigen-
specific fashion and also receive signals from activated T
lymphocytes (CD4) via CD40L [2]. Indeed, the most efficient
activation of cytotoxic CD8 lymphocytes required for tumor
clearance seems to be the result of DC licensing after the
interaction between CD40 and its ligand [3].
In this issue of Breast Cancer Research we show that
patients with breast cancer exhibit a high rate of spontaneous
apoptosis of circulating DCs [4]. Lenahan and Avigan [5]
comment on our report, highlighting the protective function of
IL-12 and CD40L against tumor-induced apoptosis. They
suggest that the increased susceptibility of blood DCs to
apoptosis might result in a diminished capacity of patients to
respond to vaccines that depend on in vivo loading of DCs
and recommend the use of DCs conditioned ex vivo to
circumvent this problem. One alternative is the use of
adjuvant cytokines or CD40L to treat DCs. Indeed, in vitro
stimulation with CD40L has been demonstrated to enhance
the efficiency of DCs as antigen-presenting cells (APCs) for
anti-tumoral immunization [6].
From an immunotherapy perspective such data are particularly
relevant because DC-based therapies are being evaluated as
vaccine adjuvants and are therefore being aggressively
pursued in the treatment of a wide range of malignancies
including breast cancer [7]. The design of DC vaccines to
prevent the recurrence or achieve the regression of already
existing tumors has been a major goal of immunotherapy.
Blood DCs have been proposed for immunotherapy protocols
because they offer the theoretical advantage of being in their
natural state of differentiation and are thus capable of orches-
trating immune responses in a more physiological manner.
Given that tumors are suppressive to DCs and induce
significant alterations of the blood DC compartment, one
must ask whether therapies using endogenous DCs can
really enhance host immunity and delay or prevent tumor
recurrence. In fact, immunotherapy protocols using
circulating DC preparations have produced limited clinical
responses [8]. Interestingly, it has been demonstrated that
whereas circulating DCs isolated from patients with cancer
are deficient in their function, DCs conditioned in vitro in the
absence of tumor products have the capacity to induce
robust immune responses [9,10]. We have therefore
postulated that ex vivo conditioning of APCs should remain
the most plausible approach in an effort to avoid tumor-
induced suppression in vivo, and CD40 ligation may provide
the optimal maturation signal to achieve this aim [11].
In addition, other CD40–CD40L interactions may have
further effects on anti-tumor responses. For example, we have
shown elsewhere that CD40 expression and engagement in
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a tumoral environment might be responsible for the
accumulation of an immature (and dysfunctional) population
within the lineage-negative HLA-DR-positive (commonly
referred to as DCs) compartment in patients with breast
cancer and other tumors [11]. We described these cells as
DR+ICs (HLA-DR positive immature cells), having a deficient
but recoverable antigen-presenting capacity. Interestingly,
DR+ICs express higher levels of CD40 than genuine blood
DCs, and are therefore potentially more responsive to the
effects of CD40 ligation. We have proposed that the
significant accumulation of DR+ICs in blood of these patients
is the net result of tumor-induced apoptosis of DCs and
resistance of immature APCs to apoptosis mediated by
CD40–CD40L interactions. When measured in circulation,
the number of DR+ICs often exceeds that of genuine blood
DCs. Most importantly, we established that the antigen-
presenting function in this population may be recovered by
exposure to increased levels of CD40L in vitro [12].
If we accept that ex vivo conditioning is required for effective
immunotherapy, the next issue is to determine the optimal
conditioning stimulus. As indicated above, immature APCs
that are resistant to tumor-induced apoptosis and are thus
highly abundant in patients with breast cancer are exquisitely
sensitive to the effects of CD40 ligation [11]. Importantly,
CD40L but no other maturation stimuli (inflammatory
cytokines, CpG DNA, poly(I:C), lipopolysaccharide) induced
both a vigorous activation of DCs and the robust functional
maturation of immature APCs, as shown by the upregulation
of the antigen-presenting machinery, the secretion of IL-12
and enhanced T cell stimulatory capacities.
These data not only confirm that the help signal provided by
CD40 engagement is one of the most potent stimuli for the
maturation of DCs and other APCs (immature cells) that are
abundant in cancer patients [11] but may also be important in
preventing DC apoptosis induced by tumor products [4].
These findings advance CD40L as one of the prime
candidates for the ex vivo conditioning of cellular vectors for
immunotherapy.
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